Sintetica - Patented Ophthalmic Surgical Drug Candidate - Ownership and Business Overview

Life ScienceCompany

Sintetica - Patented Ophthalmic Surgical Drug Candidate Ownership

Who owns Sintetica - Patented Ophthalmic Surgical Drug Candidate?

Sintetica - Patented Ophthalmic Surgical Drug Candidate is owned by Harrow. It was acquired on July 27, 2021.

Sintetica - Patented Ophthalmic Surgical Drug Candidate Business Overview

Where is Sintetica - Patented Ophthalmic Surgical Drug Candidate headquartered?

Sintetica - Patented Ophthalmic Surgical Drug Candidate is headquartered in United States.

What sector is Sintetica - Patented Ophthalmic Surgical Drug Candidate in?

Sintetica - Patented Ophthalmic Surgical Drug Candidate is a life science company.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 397 acquisitions of life science companies in 2021, including 46 acquisitions by private equity firms, and 351 by strategics.

Sintetica - Patented Ophthalmic Surgical Drug Candidate


United States,

Sintetica's Patented Ophthalmic Surgical Drug Candidate provides ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections.


 Subscribe to unlock this and 208,718
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Sintetica - Patented Ophthalmic Surgical Drug Candidate

Life Science Companies , United States Companies